Home The Word Brain My Amedeo FAQ Privacy About   

2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.

  Breast Cancer

  Free Subscription

Articles published in J Clin Invest

Retrieve available abstracts of 39 articles:
HTML format

Single Articles

    May 2024
  1. MARCHESE E, Demehri S
    Posttranslational protein modifications as gatekeepers of cancer immunogenicity.
    J Clin Invest. 2024;134:e180914.
    PubMed     Abstract available

    April 2024
    Surviving without BRCA2: MLH1 gets R-looped in to curtail genomic instability.
    J Clin Invest. 2024;134:e179325.
    PubMed     Abstract available

    March 2024
  3. ZHU Y, Banerjee A, Xie P, Ivanov AA, et al
    Pharmacological suppression of the OTUD4/CD73 proteolytic axis revives antitumor immunity against immune-suppressive breast cancers.
    J Clin Invest. 2024;134:e176390.
    PubMed     Abstract available

    February 2024
  4. LI Z, Metzger Filho O, Viale G, dell'Orto P, et al
    HER2 heterogeneity and treatment response-associated profiles in HER2-positive breast cancer in the NCT02326974 clinical trial.
    J Clin Invest. 2024 Feb 1:e176454. doi: 10.1172/JCI176454.
    PubMed     Abstract available

    January 2024
  5. LUO M, Bao L, Xue Y, Zhu M, et al
    ZMYND8 protects breast cancer stem cells against oxidative stress and ferroptosis through activation of NRF2.
    J Clin Invest. 2024;134:e171166.
    PubMed     Abstract available

  6. PEYVANDI S, Bulliard M, Yilmaz A, Kauzlaric A, et al
    Tumor-educated Gr1+CD11b+ cells drive breast cancer metastasis via OSM/IL6-JAK-induced cancer cell plasticity.
    J Clin Invest. 2024 Jan 18:e166847. doi: 10.1172/JCI166847.
    PubMed     Abstract available

    December 2023
  7. FARES J, Petrosyan E, Kanojia D, Dmello C, et al
    Metixene is an incomplete autophagy inducer in preclinical models of metastatic cancer and brain metastases.
    J Clin Invest. 2023;133:e161142.
    PubMed     Abstract available

    November 2023
  8. LI M, Nishimura T, Takeuchi Y, Hongu T, et al
    FXYD3 functionally demarcates an ancestral breast cancer stem cell subpopulation with features of drug-tolerant persisters.
    J Clin Invest. 2023;133:e166666.
    PubMed     Abstract available

    October 2023
  9. KINA E, Laverdure JP, Durette C, Lanoix J, et al
    Breast cancer immunopeptidomes contain numerous shared tumor antigens.
    J Clin Invest. 2023 Oct 31:e166740. doi: 10.1172/JCI166740.
    PubMed     Abstract available

  10. IRANI S, Tan W, Li Q, Toy W, et al
    Somatic estrogen receptor alpha mutations that induce dimerization promote receptor activity and breast cancer proliferation.
    J Clin Invest. 2023 Oct 26:e163242. doi: 10.1172/JCI163242.
    PubMed     Abstract available

  11. ZHAO N, Kabotyanski EB, Saltzman AB, Malovannaya A, et al
    Targeting EIF4A triggers an interferon response to synergize with chemotherapy and suppress triple-negative breast cancer.
    J Clin Invest. 2023 Oct 24:e172503. doi: 10.1172/JCI172503.
    PubMed     Abstract available

  12. XIONG SY, Wen HZ, Dai LM, Lou YX, et al
    A brain-tumor neural circuit controls breast cancer progression in mice.
    J Clin Invest. 2023 Oct 17:e167725. doi: 10.1172/JCI167725.
    PubMed     Abstract available

    September 2023
  13. CHANG HL, Schwettmann B, McArthur HL, Chan IS, et al
    Antibody-drug conjugates in breast cancer: overcoming resistance and boosting immune response.
    J Clin Invest. 2023;133:e172156.
    PubMed     Abstract available

  14. BAO L, Kumar A, Zhu M, Peng Y, et al
    SAP30 promotes breast tumor progression by bridging the transcriptional corepressor SIN3 complex and MLL1.
    J Clin Invest. 2023;133:e168362.
    PubMed     Abstract available

    July 2023
  15. DEVARAJAN R, Izzi V, Peltoketo H, Rask G, et al
    Targeting collagen XVIII improves the efficiency of ErbB inhibitors in breast cancer models.
    J Clin Invest. 2023 Jul 27:e159181. doi: 10.1172/JCI159181.
    PubMed     Abstract available

  16. YANG M, Li Y, Kong L, Huang S, et al
    Inhibition of DPAGT1 suppresses HER2 shedding and trastuzumab resistance in human breast cancer.
    J Clin Invest. 2023;133:e164428.
    PubMed     Abstract available

    June 2023
  17. LIN Q, Liu T, Wang X, Hou G, et al
    Long noncoding RNA HITT coordinates with RGS2 to inhibit PD-L1 translation in T cell immunity.
    J Clin Invest. 2023;133:e162951.
    PubMed     Abstract available

    April 2023
  18. BERTOLINI I, Perego M, Nefedova Y, Lin C, et al
    Intercellular hif1alpha reprograms mammary progenitors and myeloid immune evasion to drive high-risk breast lesions.
    J Clin Invest. 2023;133:e164348.
    PubMed     Abstract available

    March 2023
  19. ZHENG C, Wei Y, Zhang P, Xu L, et al
    CRISPR/Cas9 screen uncovers functional translation of cryptic lncRNA-encoded open reading frames in human cancer.
    J Clin Invest. 2023;133:e159940.
    PubMed     Abstract available

    February 2023
  20. NANDI I, Smith HW, Sanguin-Gendreau V, Ji L, et al
    Coordinated activation of c-Src and FOXM1 drives tumor cell proliferation and breast cancer progression.
    J Clin Invest. 2023 Feb 16:e162324. doi: 10.1172/JCI162324.
    PubMed     Abstract available

    December 2022
  21. COLLIGAN SH, Amitrano AM, Zollo RA, Peresie J, et al
    Inhibiting the biogenesis of myeloid-derived suppressor cells enhances immunotherapy efficacy against mammary tumor progression.
    J Clin Invest. 2022;132:e158661.
    PubMed     Abstract available

  22. HORVAT NK, Lesinski GB
    Bring on the brequinar: an approach to enforce the differentiation of myeloid-derived suppressor cells.
    J Clin Invest. 2022;132:e165506.
    PubMed     Abstract available

    October 2022
  23. ARAUJO AM, Abaurrea A, Azcoaga P, Lopez-Velazco JI, et al
    Stromal oncostatin M cytokine promotes breast cancer progression by reprogramming the tumor microenvironment.
    J Clin Invest. 2022;132.

  24. SHARMA S, Opyrchal M, Lu X
    Harnessing tumorous flaws for immune supremacy: is miRNA-155 the weak link in breast cancer progression?
    J Clin Invest. 2022;132.
    PubMed     Abstract available

    August 2022
  25. WANG J, Wang Q, Guan Y, Sun Y, et al
    Breast cancer cell-derived microRNA-155 suppresses tumor progression via enhancing immune cell recruitment and anti-tumor function.
    J Clin Invest. 2022 Aug 4. pii: 157248. doi: 10.1172/JCI157248.
    PubMed     Abstract available

    June 2022
  26. LU Z, Mao W, Yang H, Santiago-O'Farrill JM, et al
    SIK2 inhibition enhances PARP inhibitor activity synergistically in ovarian and triple-negative breast cancers.
    J Clin Invest. 2022;132.
    PubMed     Abstract available

    May 2022
  27. SZCZEPANIAK P, Siedlinski M, Hodorowicz-Zaniewska D, Nosalski R, et al
    Breast cancer chemotherapy induces vascular dysfunction and hypertension through NOX4 dependent mechanism.
    J Clin Invest. 2022 May 26. pii: 149117. doi: 10.1172/JCI149117.
    PubMed     Abstract available

    April 2022
  28. WAARTS MR, Stonestrom AJ, Park YC, Levine RL, et al
    Targeting mutations in cancer.
    J Clin Invest. 2022;132.
    PubMed     Abstract available

    March 2022
  29. HUANG C, Hu F, Song D, Sun X, et al
    EZH2-triggered methylation of SMAD3 promotes its activation and tumor metastasis.
    J Clin Invest. 2022;132.
    PubMed     Abstract available

  30. ABU-LIBDEH B, Jhujh SS, Dhar S, Sommers JA, et al
    RECON syndrome is a genome instability disorder caused by mutations in the DNA helicase RECQL1.
    J Clin Invest. 2022;132.
    PubMed     Abstract available

  31. SUN S, Brazhnik K, Lee M, Maslov AY, et al
    Single-cell analysis of somatic mutation burden in mammary epithelial cells of pathogenic BRCA1/2 mutation carriers.
    J Clin Invest. 2022;132.
    PubMed     Abstract available

    February 2022
  32. ARAUJO AM, Abaurrea A, Azcoaga P, Lopez-Velazco JI, et al
    Stromal Oncostatin M cytokine promotes breast cancer progression by reprogramming the tumour microenvironment.
    J Clin Invest. 2022 Feb 22. pii: 148667. doi: 10.1172/JCI148667.
    PubMed     Abstract available

    January 2022
  33. YUE Z, Niu X, Yuan Z, Qin Q, et al
    RSPO2 and RANKL signal through LGR4 to regulate osteoclastic premetastatic niche formation and bone metastasis.
    J Clin Invest. 2022;132.
    PubMed     Abstract available

  34. XU J, Su SM, Zhang X, Chan UI, et al
    ATP11B inhibits breast cancer metastasis in a mouse model by suppressing externalization of non-apoptotic phosphatidylserine.
    J Clin Invest. 2022 Jan 13. pii: 149473. doi: 10.1172/JCI149473.
    PubMed     Abstract available

    December 2021
  35. RAE JM, Lippman ME
    The role of estrogen receptor signaling in suppressing the immune response to cancer.
    J Clin Invest. 2021;131.
    PubMed     Abstract available

  36. KISHIKAWA T, Higuchi H, Wang L, Panch N, et al
    WWP1 inactivation enhances efficacy of PI3K inhibitors while suppressing their toxicities in breast cancer models.
    J Clin Invest. 2021;131.
    PubMed     Abstract available

    November 2021
  37. EL-HOUJEIRI L, Biondini M, Paquette M, Kuasne H, et al
    Folliculin impairs breast tumor growth by repressing TFE3-dependent induction of the Warburg effect and angiogenesis.
    J Clin Invest. 2021;131.
    PubMed     Abstract available

    March 2021
  38. MUSCARELLA AM, Aguirre S, Hao X, Waldvogel SM, et al
    Exploiting bone niches: progression of disseminated tumor cells to metastasis.
    J Clin Invest. 2021;131.
    PubMed     Abstract available

  39. KARTHIKEYAN S, Waters IG, Dennison L, Chu D, et al
    Hierarchical tumor heterogeneity mediated by cell contact between distinct genetic subclones.
    J Clin Invest. 2021;131.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.